FDA grants pri­or­i­ty re­view to Lyn­parza com­bo ther­a­py for metasta­t­ic prostate can­cer

As­traZeneca and Mer­ck’s top-sell­ing PARP in­hibitor Lyn­parza is pos­si­bly on its way to win­ning reg­u­la­to­ry ap­proval for yet an­oth­er in­di­ca­tion.

The FDA has ac­cept­ed the sup­ple­men­tal new drug ap­pli­ca­tion and grant­ed a pri­or­i­ty re­view to Lyn­parza com­bi­na­tion ther­a­py for pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, the com­pa­nies an­nounced Tues­day.

In the US, prostate can­cer is the sec­ond most com­mon can­cer in male pa­tients, and near­ly 10-20% of men with ad­vanced prostate can­cer are es­ti­mat­ed to de­vel­op cas­tra­tion-re­sis­tant prostate can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.